



Cover image: Quantification of serum levels of osteoprotegerin (OPG), RANKL and parathormone (PTH) in hTNFtg and VDR<sup>-/-</sup>hTNFtg mice (n=8/group)  
See p 1126.

## Editor

Tore K Kvien

## Associate Editors

Francis Berenbaum  
Hans Bijlsma  
Dimitrios Boupas  
Gerd Burmester  
Mary Crow  
Iain McInnes

## Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 8.11

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2011 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Newgen and printed in the UK on acid-free paper from sustainable forests by Latimer Trend, Plymouth

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Mercury International Ltd. Periodicals postage paid at Rahway, NJ, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases* Mercury International Ltd, 365 Blair Road, Avenel NJ 07001, USA.

## Contents

Volume 70 Issue 6 | ARD June 2011

## Editorials

- 881** Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start?  
*M T Nurmohamed, G Kitas*
- 884** RAID: a valid tool to quantify the impact of rheumatoid arthritis. But what impact will it have on the core set for trials?  
*M Boers*

## Viewpoint

- 886** Reporting of long-term extension studies: lack of consistency calls for consensus  
*M H Buch, D Alekha, P Emery, J S Smolen*

## Recommendations

- 891** Treating rheumatoid arthritis to target: the patient version of the international recommendations  
*M P T de Wit, J S Smolen, L Gossec, D M F M van der Heijde*
- 896** 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis  
*J Braun, R van den Berg, X Baraliakos, H Boehm, R Burgos-Vargas, E Collantes-Estevéz, H Dagfinrud, B Dijkman, M Dougados, P Emery, P Geher, M Hammoudeh, R D Inman, M Jongkees, M A Khan, U Kiltz, T K Kvien, M Leirisalo-Repo, W P Maksymowych, I Oliveri, K Pavelka, J Sieper, E Stanislawski-Biernat, D Wendling, S Özgöçmen, C van Drogen, B J van Royen, D van der Heijde*
- 905** 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis  
*D van der Heijde, J Sieper, W P Maksymowych, M Dougados, R Burgos-Vargas, R Landewé, M Rudwaleit, J Braun; for the Assessment of SpondyloArthritis international Society*

## Consensus

- 909** Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis  
*M H Buch, J S Smolen, N Betteridge, F C Breedveld, G Burmester, T Dörner, G Ferraccioli, J-E Gottenberg, J Isaacs, T K Kvien, X Mariette, E Marin-Mola, K Pavelka, P P Tak, D van der Heijde, R F van Vollenhoven, P Emery; for the Rituximab Consensus Expert Committee*

## Review

- 921** Assessing health-related quality of life in hand osteoarthritis: a literature review  
*M Michon, E Maheu, F Berenbaum*

## Clinical and epidemiological research

- 929** The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study  
*J Lindhardtsen, O Ahleoff, G H Gislason, O R Madsen, J B Olesen, C Torp-Pedersen, P R Hansen*
- 935** Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative  
*L Gossec, S Paternotte, G J Aanerud, A Balanescu, D T Boupas, L Carmona, M de Wit, B A C Dijkman, M Dougados, M Englbrecht, F Gogus, T Heiberg, C Hernandez, J R Kirwan, E M Mola, M M Cernic, K Otsa, G Schett, M Scholte-Voshaar, T Sokka, G von Krause, G A Wells, T K Kvien*
- 943** Prevalence of spondyloarthritis and its subtypes in southern Sweden  
*E Haglund, A B Bremander, I F Petersson, B Strömbeck, S Bergman, L T H Jacobsson, A Turkiewicz, P Geborek, M Englund*
- 949** Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort  
*M Z Cader, A Filer, J Hazlehurst, P de Pablo, C D Buckley, K Raza*
- 956** The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study  
*W G Dixon, A Kézouli, S Bernatsky, S Suissa*

- 961** SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus  
*J G Hanly, M B Urowitz, D Jackson, S C Bae, C Gordon, D J Wallace, A Clarke, S Bernatsky, A Vasudevan, D Isenberg, A Rahman, J Sanchez-Guerrero, J Romero-Diaz, J T Merrill, P R Fortin, D D Gladman, I N Bruce, K Steinsson, M Khamashia, G S Alarcón, B Fessler, M Petri, S Manzi, O Nived, G Sturfelt, R Ramsey-Goldman, M A Dooley, C Ararow, R Van Vollenhoven, M Ramos-Casals, A Zoma, K Kalunian, V Farewell; for the Systemic Lupus International Collaborating Clinics (SLICC)*
- 968** EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome  
*R Seror, P Ravnaud, X Mariette, H Bootsma, E Theander, A Hansen, M Ramos-Casals, T Dörner, S Bombardieri, E Hachulla, J G Brun, A A Kruijs, S Praprotnik, M Tomsic, J-E Gottenberg, V Devauchelle, S Devita, C Vollenweider, T Mandl, A Tzioufas, S Carsons, A Saraux, N Sutcliffe, C Vitali, S J Bowman; on behalf of the EULAR Sjögren's Task Force*
- 973** Predicting the outcome of ankylosing spondylitis therapy  
*N Vastesaeger, D van der Heijde, R D Inman, Y Wang, A Deadhar, B Hsu, M U Rahman, B Dijkman, P Geusens, B V Cruysen, E Collantes, J Sieper, J Braun*
- 982** Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI  
*L M Wildi, J-P Raynaud, J Martel-Pelletier, A Beaulieu, L Bessette, F Morin, F Abram, M Dorais, J-P Pelletier*
- 990** Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: a population-based study  
*J A Avila-Zubiza, M Abrahamowicz, H K Choi, M M Rahman, M-P Sylvestre, J M Esdaile, D Lacaille*
- 996** Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial  
*V Strand, J S Smolen, R F van Vollenhoven, P Mease, G R Burmester, F Hiepe, D Khanna, E Nikai, G Coteur, M Schiff*
- 1003** Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial  
*R F Spiera, J K Gordon, J N Mersten, C M Magro, M Mehta, H F Wildman, S Kloiber, K A Kircu, S Lyman, M K Crow*
- 1010** How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?  
*M Neovius, J F Simard, J Askeling; for the ARTIS Study Group*
- 1016** Evidence to support *IL-13* as a risk locus for psoriatic arthritis but not psoriasis vulgaris  
*J Bowes, S Eyre, E Flynn, P Ho, S Salahi, R W Warren, H Marzo-Ortega, L Coates, R McManus, A W Ryan, D Kane, E Kordowich, N McHugh, O FitzGerald, J Packham, A W Morgan, C E M Griffiths, I N Bruce, J Worthington, A Barton*
- 1020** Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study  
*M A De Vera, H Choi, M Abrahamowicz, J Kopec, M V Goycochea-Robles, D Lacaille*

## MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>



COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)



equator network



recycle  
When you have finished with this please recycle it

- 1025** Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis  
*T E Toms, V F Panoulas, J P Smith, K M J Douglas, G S Metsios, A Stavropoulos-Kalinoglou, G D Kitas*
- 1033** Hand osteoarthritis and MRI: development and first validation step of the proposed Oslo Hand Osteoarthritis MRI score  
*I K Haugen, S Lillegraven, B Slatkowsky-Christensen, E A Haavardsholm, S Sesseng, T K Kvien, D van der Heijde, P Bøyesen*
- 1039** The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study  
*N B Klarenbeek, M Güler-Yüksel, S M van der Kooij, K H Han, H K Ronday, P J S M Kerstens, P E H Seys, T W J Huizinga, B A C Dijkmans, C F Allaart*
- 1047** The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients  
*R Gunnarsson, Ø Molberg, I-M Gilboe, J T Gran; PAHNORI Study Group\**
- 1052** Fcγ receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins  
*L Laurent, C Clavel, O Lemaire, F Anquetil, M Cornillet, L Zabraniecki, L Nogueira, B Fournié, G Serre, M Sebbag*
- 1060** Self-management of fatigue in rheumatoid arthritis: a randomised controlled trial of group cognitive-behavioural therapy  
*S Hewlett, N Ambler, C Almeida, A Cliss, A Hammond, K Kitchen, B Knops, D Pope, M Spears, A Swinkels, J Pollock*
- 1068** Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic disease  
*C G S Saad, E F Borba, N E Aikawa, C A Silva, R M R Pereira, A L Calich, J C B Moraes, A C M Ribeiro, V S T Viana, S G Pasoto, J F Carvalho, I L A França, L K N Guedes, S K Shinjo, P D Sampaio-Barros, M T Caleiro, C R Gonçalves, R Fuller, M Levy-Neto, M do C S Timenetsky, A R Precioso, E Bonfá*
- 1074** Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries  
*T A Stamm, M Mattsson, C Mihai, J Stöcker, A Binder, B Bauernfeind, G Stummvoll, G Gard, R Hesselstrand, G Sandqvist, O Draghicescu, A M Gherghe, M Voicu, K P Machold, O Distler, J S Smolen, C Boström*
- 1080** Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to other patient-reported outcomes in a register of patients with rheumatoid arthritis  
*T Heilberg, C Austad, T K Kvien, T Uhlig*
- 1083** Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study  
*A Ruffatti, T D Ross, M Ciprian, M T Bertero, S Sciascia, S Scarfato, C Montecucco, S Rossi, P Caramaschi, D Biasi, A Doria, M Rampudda, M Nuzzo, F Fischetti, U Picallo, A Bricato, E Salvan, V Pengo, P Meroni, A Tincani; Antiphospholipid Syndrome Study Group of the Italian Society of Rheumatology*
- 1087** The presence of total knee or hip replacements due to osteoarthritis enhances the positive association between hand osteoarthritis and atherosclerosis in women: the AGES-Reykjavik study  
*H Jonsson, G P Helgadóttir, T Aspelund, G Eiriksdóttir, S Sigurdsson, K Siggeirsdóttir, T Ingvarsson, T B Harris, L Launer, V Gudnason*
- 1091** Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study  
*F McQueen, R Lloyd, A Doyle, E Robinson, M Lobo, M Exeter, W J Taylor, P Jones, I R Reid, N Dalbeth*
- 1095** Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis  
*B A Fisher, D Plant, M Brode, R F van Vollenhoven, L Mathsson, D Symmons, K Lundberg, J Rönnelid, P J Venables*
- 1099** Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA st4  
*M F Bakker, J W G Jacobs, P M J Welsing, S A Vreugdenhil, C van Booma-Frankfort, S P Linn-Rasker, E Ton, F P J G Laféber, J W J Bijlsma; on behalf of the Utrecht Arthritis Cohort Study Group*
- 1104** Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis  
*E N Le, F M Wigley, A A Shah, F Boin, L K Hummers*
- 1108** Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study  
*I-H Song, F Heldmann, M Rudwaleit, H Haibel, A Weiβ, J Braun, J Sieper*

- 1111** Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level  
*M Gutierrez, E Filippucci, F Salaffi, L D Gese, W Grassi*

## Basic and translational research

- 1115** An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis  
*V Codullo, H M Baldwin, M D Singh, A R Fraser, C Wilson, A Gilmour, A J Hueber, C Bonino, I B McInnes, C Montecucco, G J Graham*
- 1122** Vitamin D receptor regulates TNF-mediated arthritis  
*K Zwerina, W Baum, R Axmann, G R Heiland, J H Distler, J Smolen, S Hayer, J Zwerina, G Schett*
- 1130** Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane  
*A Crilly, S E Robertson, J H Reilly, J A Gracie, W-Q Lai, B P Leung, P F Life, I B McInnes*
- 1138** Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus  
*A Mathian, Z Amoura, E Adam, F Colaone, M F M Hoekman, O Dhellin, P Vandepapelière, J Haroche, J-C Piette, P Lebon, G Grouard-Vogel*
- 1144** Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis  
*D de Seny, M Sharif, M Fillet, G Cobraiville, M-A Meuwis, R Marée, J-P Hauzeur, L Wehenkel, E Louis, M-P Merville, J Kirwan, C Ribbens, M Malaise*
- 1153** Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis  
*S Vosslander, H G Raterman, T C T M van der Pouw Kraan, M W J Schreurs, B M E von Blomberg, M T Nurmohamed, W F Lems, B A C Dijkmans, A E Voskuyl, C L Verweij*
- 1160** Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab  
*M M J Herenius, R M Thurlings, C A Wijbrandts, R J Bennink, S E Dolmen, C Voermans, D Wouters, E S Izmailova, D M Gerlag, B L F van Eck-Smit, P P Tak*

## Letters

- 1163** Coincidence of calcium pyrophosphate and monosodium urate crystals in the synovial fluid of patients with gout determined by the cyto centrifugation technique  
*C Robier, M Neubauer, F Quehenberger, F Rainer*
- 1164** Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab  
*A Ogata, A Morishima, T Hirano, Y Hishitani, K Hagihara, Y Shima, M Narazaki, T Tanaka*
- 1165** Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNFα blockade: results from a prospective cohort study  
*P Welsh, M J L Peters, I B McInnes, W F Lems, P T Lips, G McKellar, S Knox, A M Wallace, B A C Dijkmans, M T Nurmohamed, N Sattar*
- 1167** Hormone replacement therapy in postmenopausal women with rheumatoid arthritis stabilises bone mineral density by digital x-ray radiogrammetry in a randomised controlled trial  
*H Forsblad-d'Elia, H Carlsten*
- 1168** Variable expression and treatment of PAPA syndrome  
*M A Schellevis, M Stoffels, E P A H Hoppenreijns, E Bodar, A Simon, J W M van der Meer*
- 1170** Collagen-induced arthritis is not impaired in mast cell-deficient mice  
*N Pitman, D L Asquith, G Murphy, F Y Liew, I B McInnes*
- 1172** Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits  
*T Jönsdóttir, B Sundelin, E W Henriksson, R F van Vollenhoven, I Gunnarsson*
- 1173** Bone metabolism is altered in preclinical rheumatoid arthritis  
*D van Schaardenburg, M M J Nielen, W F Lems, J W R Twisk, H W Reesink, R J van de Stadt, I E van der Horst-Bruinsma, M H M T de Koning, M R Habibub, B A C Dijkmans*